Rational use of medications: if Canada can't do it ..
作者信息
Califf Robert M
机构信息
Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC 27710, USA.
出版信息
CMAJ. 2009 Jul 7;181(1-2):15-6. doi: 10.1503/cmaj.090861.
Abstract
摘要
相似文献
1
Rational use of medications: if Canada can't do it ..
CMAJ. 2009 Jul 7;181(1-2):15-6. doi: 10.1503/cmaj.090861.
2
Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
Can J Cardiol. 2007 Jul;23(9):719-20. doi: 10.1016/s0828-282x(07)70816-4.
3
Long-term trends in use of and expenditures for cardiovascular medications in Canada.
CMAJ. 2009 Jul 7;181(1-2):E19-28. doi: 10.1503/cmaj.081913.
4
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001.
Can J Cardiol. 2003 Nov;19(12):1359-66.
5
A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
Can J Cardiol. 1997 Jan;13(1):33-45.
6
Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
Int J Clin Pract. 2010 Jan;64(2):138-40. doi: 10.1111/j.1742-1241.2009.02233.x.
7
The Canadian Cardiovascular Society and reference-based drug pricing.
Can J Cardiol. 1998 May;14(5):669-70.
8
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Lancet. 2016 Jan 2;387(10013):61-9. doi: 10.1016/S0140-6736(15)00469-9. Epub 2015 Oct 20.
9
Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.
Can J Cardiol. 2007 Jul;23(9):711-8. doi: 10.1016/s0828-282x(07)70815-2.
10
[Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
Dtsch Med Wochenschr. 2004 Feb 13;129(7):330. doi: 10.1055/s-2004-818631.
引用本文的文献
1
Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010.
Eur J Clin Pharmacol. 2014 Apr;70(4):437-43. doi: 10.1007/s00228-013-1621-6. Epub 2014 Jan 8.
2
From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006.
BMC Fam Pract. 2010 Oct 7;11:75. doi: 10.1186/1471-2296-11-75.
本文引用的文献
1
Long-term trends in use of and expenditures for cardiovascular medications in Canada.
CMAJ. 2009 Jul 7;181(1-2):E19-28. doi: 10.1503/cmaj.081913.
2
Clinical forecasting in drug development.
Nat Rev Drug Discov. 2007 Feb;6(2):107-8. doi: 10.1038/nrd2246.
3
Integrating quality into the cycle of therapeutic development.
J Am Coll Cardiol. 2002 Dec 4;40(11):1895-901. doi: 10.1016/s0735-1097(02)02537-8.
4
Unwarranted variations in healthcare delivery: implications for academic medical centres.
BMJ. 2002 Oct 26;325(7370):961-4. doi: 10.1136/bmj.325.7370.961.
5
The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost.
J Am Coll Cardiol. 2001 Oct;38(4):1012-7. doi: 10.1016/s0735-1097(01)01512-1.
6
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States.
N Engl J Med. 1994 Oct 27;331(17):1130-5. doi: 10.1056/NEJM199410273311706.
Zotero 插件